The 36-month beta value for LIPO is also noteworthy at 0.29. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for LIPO is 5.16M, and at present, short sellers hold a 3.39% of that float. The average trading volume of LIPO on November 05, 2024 was 1.09M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
LIPO) stock’s latest price update
The stock price of Lipella Pharmaceuticals Inc (NASDAQ: LIPO) has dropped by -12.80 compared to previous close of 0.39. Despite this, the company has seen a fall of -18.80% in its stock price over the last five trading days. globenewswire.com reported 2024-11-01 that PITTSBURGH, Nov. 01, 2024 (GLOBE NEWSWIRE) — Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (the “Company,” “our” or “us”), a clinical-stage biotechnology company focused on developing innovative therapies for serious diseases with unmet medical needs, today announced that it intends to effect a 1-for-8 reverse stock split of its common stock effective as of 5:00 p.m. Eastern Time on November 7, 2024 upon the filing of a certificate of amendment to the Company’s certificate of incorporation with the Secretary of State of the State of Delaware.
LIPO’s Market Performance
LIPO’s stock has fallen by -18.80% in the past week, with a monthly drop of -19.17% and a quarterly drop of -44.09%. The volatility ratio for the week is 9.70% while the volatility levels for the last 30 days are 10.65% for Lipella Pharmaceuticals Inc The simple moving average for the last 20 days is -20.00% for LIPO’s stock, with a simple moving average of -46.90% for the last 200 days.
LIPO Trading at -20.64% from the 50-Day Moving Average
After a stumble in the market that brought LIPO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -77.37% of loss for the given period.
Volatility was left at 10.65%, however, over the last 30 days, the volatility rate increased by 9.70%, as shares sank -15.99% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -34.67% lower at present.
During the last 5 trading sessions, LIPO fell by -18.80%, which changed the moving average for the period of 200-days by -64.65% in comparison to the 20-day moving average, which settled at $0.4242. In addition, Lipella Pharmaceuticals Inc saw -66.73% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LIPO starting from Kaufman Jonathan H, who purchase 10,000 shares at the price of $0.76 back on May 14 ’24. After this action, Kaufman Jonathan H now owns 898,849 shares of Lipella Pharmaceuticals Inc, valued at $7,590 using the latest closing price.
Kaufman Jonathan H, the below. of Lipella Pharmaceuticals Inc, purchase 30,000 shares at $0.79 during a trade that took place back on Mar 18 ’24, which means that Kaufman Jonathan H is holding 863,849 shares at $23,649 based on the most recent closing price.
Stock Fundamentals for LIPO
Current profitability levels for the company are sitting at:
- -3.97 for the present operating margin
- 1.0 for the gross margin
The net margin for Lipella Pharmaceuticals Inc stands at -3.91. The total capital return value is set at -560.8. Equity return is now at value -171.56, with -146.02 for asset returns.
Based on Lipella Pharmaceuticals Inc (LIPO), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -39.78. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is 87.99.
Currently, EBITDA for the company is -4.74 million with net debt to EBITDA at 0.0. When we switch over and look at the enterprise to sales, we see a ratio of 0.01. The receivables turnover for the company is 6813.9for trailing twelve months and the total asset turnover is 110.23. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.33.
Conclusion
In summary, Lipella Pharmaceuticals Inc (LIPO) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
